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(D50) were fitting parameters and studies were weighted using inverse 
variance (see Eq. 1).  
PRFS=1/(1+exp(4·γ50·(1-D/D50))) [Eq.1] 
Results: A total of ca 4000 publications were reviewed of which 15 
met the acceptance criteria, providing a total of 28 dose level 
outcome data at 1-4 time points. A total of 6/28 were using IG-IMRT, 
7/28 IMRT, 15/28 3DCRT and 6/28 were randomized trials. IG, IMRT 
and radiation dose were associated with improved PRFS at 5 years 
(Table 1), while randomized trials (yes/no), the frequency of use or 
duration of ADT were not.Only the radiation dose remained significant 
in a multivariate analysis, indicating that a pooled analysis of all 
studies was reasonable. The gradient of the dose response curve (γ50) 
was ca 1.5% at 3-7 years, and the dose required to obtain 50% PRFS 
(D50) was significantly different at 3 vs. 5 and 7 years (p<0.001) (Fig. 
1.). A reduction of 6% in PRFS per year was estimated for year 3-5 
post RT. Increased treatment margin tended to improve PRFS 
independent of IGRT use. No publication bias was evident.  
 
 
 
Conclusions: High-dose IG-IMRT was associated with superior PRFS vs. 
low-dose RT for high-risk PCa. PRFS at 3 years can potentially be used 
to predict outcome at 4-7 years. The possibility of a minor effect on 
PRFS by reducing the treatment margin could be discerned. By 
extrapolation of our model, RT to ca 85-95 Gy in equivalent dose in 2-
Gy fractions is predicted to improve PRFS for high-risk PCa, after 
which the local control plateaus and the benefit diminishes.  
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Purpose/Objective: The dose-response relationship for prostate 
radiotherapy has been demonstrated in several clinical trials with an 
advantage for high dose treatments. Established prognostic factors; 
including tumour stage, Gleason score, and PSA explain only a 
moderate proportion of the variation in outcome following prostate 
radiotherapy. There are no reliable predictors to determine which 
patients are likely to benefit from the extra dose. Prostate cancer 
exhibits regions of hypoxia with oxygen partial pressures that are 
likely to have radiobiological significance. The concept of the oxygen 
enhancement ratio is well established and it is possible that hypoxia 
biomarkers may predict which patients require dose escalation. We 
aimed to study the predictive value of intrinsic biomarkers of tumour 
hypoxia (GLUT1, HIF1α and osteopontin (OPN)) in patients treated 
with radiotherapy for localised prostate cancer. 
Materials and Methods: Paraffin embedded prostate biopsies were 
collected from patients enrolled into a trial of external beam 
radiotherapy (EBRT) versus combined EBRT followed by a high dose 
rate (HDR) brachytherapy boost.  
Immunohistochemical staining was performed for GLUT1, HIF1αand 
OPN using monoclonal antibodies. Tumours were assessed for 
biomarker expression by two independent investigators, blinded to 
patient outcome and scored as negative or positive depending upon 
the proportion of cells staining for the marker in question. 
Biochemical relapse free interval for all patients was determined 
using the Kaplan-Meier method. 
Results: 191 samples were included in the analysis. Hif1α, Glut1 and 
OPN expression were all significantly associated with a shorter 
biochemical relapse free interval (see figure and table). High dose 
radiotherapy (EBRT plus HDR boost) was advantageous over 
conventional dose radiotherapy (EBRT alone) for patients that 
exhibited OPN expression (p=0.017) but not for patients with negative 
OPN staining (p=0.349). Conversely, for GLUT1, high dose 
radiotherapy was only advantageous over conventional dose 
radiotherapy for patients that lacked GLUT1 expression (p=0.006).  
 
 
  
Conclusions: Overall, expression of OPN, HIF1α or GLUT1 confers a 
poorer prognosis for patients receiving prostate radiotherapy 
compared to those that do not express these hypoxia biomarkers. 
Furthermore, these data generate the following hypothesis: OPN 
becomes positive in the presence of mild/moderate hypoxia, GLUT1 
only becomes positive under conditions of severe hypoxia. Therefore, 
If both OPN and GLUT1 are negative (i.e. minimal hypoxia), there is 
no benefit from dose escalation. If OPN is positive and GLUT1 is 
negative (moderate hypoxia), there is a benefit for dose escalation. 
However, If GLUT1 is positive (severe hypoxia), there is no benefit 
from dose escalation because patients will do badly despite very high 
doses of radiotherapy. Further evaluation using an independent data 
set is ongoing.  
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Purpose/Objective: Daily location of the target volume has become a 
usual clinical practice after introduction of portal imaging devices. 
The actual information on the day of treatment is used to relocate the 
patient to maximize target coverage. However, relocation is not 
capable to account for large deformations of structures of interest, 
and the therapeutic ratio remains lower then desired. We propose a 
method of generating triple-arc IMAT plans to treat prostate cancer 
